Researchers at Dana - Farber / Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who
received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only.
Omer, Tzannou and their colleagues conducted a clinical trial to determine the safety and effectiveness of pre-prepared virus - specific cells to treat five viral infections simultaneously in patients who had
received a hematopoietic stem cells transplant.
Not exact matches
But for blood cancer patients who
receive donor
hematopoietic stem cell transplants as part of their treatment, graft - versus - host disease (GVHD) often hampers their recovery.
Patients who
receive HSCT
receive high doses of chemotherapy, with or without radiation, followed by infusion of
hematopoietic stem cells (HSCs)-- rare cells that reside within the bone marrow and are capable of producing all varieties of blood cells.
When patients
receive a bone marrow transplant, they are getting a new population of
hematopoietic stem cells.